Advertisement

Journal of General Internal Medicine

, Volume 17, Issue 4, pp 293–301 | Cite as

Rational treatment choices for non-major depressions in primary care

An evidence-based review
  • Ronald T. Ackermann
  • John W. WilliamsJr.Email author
Review

Abstract

OBJECTIVE: This review synthesizes available evidence for managing clinically significant dysphoric symptoms encountered in primary care, when formal criteria for major depression or dysthymia are not met. Discussion is focused on premenstrual dysphoric disorder (PMDD) and minor depression because of their significant prevalence in the primary care setting and the lack of clear practice guidelines for addressing each illness.

DESIGN: English language literature from prior systematic reviews was supplemented by searching medline, embase, the Cochrane Controlled Trials Registry, the Agency for Healthcare Research and Quality National Guideline Clearinghouse, and bibliographies of selected papers. Studies addressing the natural history or treatment of minor depression or PMDD were selected for review. Data were abstracted by 1 of 2 independent reviewers and studies were synthesized qualitatively.

RESULTS: Five individual studies that compared anti-depressant or psychological treatments to placebo in patients with minor depression suggest short-term improvements in depressive symptoms with paroxetine, problem-solving therapy, and cognitive behavioral therapy, but not with amitryptiline. Modest benefits on mental health function were reported with paroxetine and with problem-solving therapy, but only in patients with severe functional impairment at baseline. Twenty-four controlled trials were identified that compared antidepressant or psychological treatments to placebo in patients with premenstrual dysphoric disorder. Pooled results from a recent systematic review of 15 randomized controlled trials and one additional trial abstract provide strong evidence for a significantly greater improvement in physical and psychological symptoms with serotonin-selective reuptake inhibitor medications when compared with placebo. Individual trials also suggest significantly greater improvements in symptom scores with venlafaxine, but not with tricyclic antidepressants.

CONCLUSIONS: The limited evidence base for minor depression provides only mixed support for a small to moderate benefit for few antidepressant medications and psychological treatments tested. For the treatment of severe psychological or physical symptoms causing functional impairment in patients with PMDD, sertraline and fluoxetine are clearly beneficial in carefully selected patients.

Key words

depression depressive disorder premenstrual syndrome antidepressive agents psychotherapy complementary therapies 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Williams JW Jr., Mulrow CD, Chiquette E, Noel PH, Aguilar C, Cornell J. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med. 2000;132:743–56.PubMedGoogle Scholar
  2. 2.
    Mulrow CD, Williams JW Jr., Trivedi M, et al. Treatment of depression: new pharmacotherapies. AHCPR Publication No. 99-E014. Rockville, Md: Agency for Health care Policy and Research; 1999.Google Scholar
  3. 3.
    Depression Guideline Panel. Depression in primary care. Vol 2: Treatment of Major Depression. Clinical Practice Guideline, no. 5. Rockland, Md: U.S. Department of Health and Human Services, Agency for Health Care Policy and Research; 1993.Google Scholar
  4. 4.
    Beck DA, Koenig HG. Minor depression: a review of the literature. Int J Psychiatry Med. 1996;26:177–209.PubMedCrossRefGoogle Scholar
  5. 5.
    Crum RM, Cooper-Patrick L, Ford DE. Depressive symptoms among general medical patients: prevalence and one-year outcome. Psychosom Med. 1994;56:109–17.PubMedGoogle Scholar
  6. 6.
    Depression Guideline Panel. Depression in primary care. Vol 1: Detection and Diagnosis. Clinical Practice Guideline, no. 5. Rockville, Md: U.S. Department of Health and Human Services, Agency for Health Care Policy and Research; 1993.Google Scholar
  7. 7.
    Pincus HA, Davis WW, McQueen LE. ‘Subthreshold’ mental disorders. A review and synthesis of studies on minor depression and other ‘brand names’. Br J Psychiatry. 1999;174:288–96.PubMedCrossRefGoogle Scholar
  8. 8.
    Maier W, Gansicke M, Weiffenbach O. The relationship between major and subthreshold variants of unipolar depression. J Affect Disord. 1997;45:41–51.PubMedCrossRefGoogle Scholar
  9. 9.
    Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA. 1989;262:914–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Johnson J, Weissman MM, Klerman GL. Service utilization and social morbidity associated with depressive symptoms in the community. JAMA. 1992;267:1478–83.PubMedCrossRefGoogle Scholar
  11. 11.
    Williams JW Jr., Rost K, Dietrich AJ, Ciotti MC, Zyzanski SJ, Cornell J. Primary care physicians’ approach to depressive disorders. Effects of physician specialty and practice structure. Arch Fam Med. 1999;8:58–67.PubMedCrossRefGoogle Scholar
  12. 12.
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4th ed. Washington, DC: American Psychiatric Press; 1994.Google Scholar
  13. 13.
    Jarrett RB. Psychosocial aspects of depression and the role of psychotherapy. J Clin Psychiatry. 1990;51:26S-35S.Google Scholar
  14. 14.
    Mynors-Wallis LM, Gath DH, Lloyd-Thomas AR, Tomlinson D. Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care. BMJ. 1995;310:441–5.PubMedGoogle Scholar
  15. 15.
    Broadhead WE, Blazer DG, George LK, Tse CK. Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA. 1990;264:2524–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Association of Professors of Gynecology and Obstetrics. Depressive disorders in women: diagnosis, treatment, and monitoring. Washington, DC: Association of Professors of Gynecology and Obstetrics; 1997.Google Scholar
  17. 17.
    Dimmock PW, Wyatt KM, Jones PW, O’Brien PM. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet. 2000;356:1131–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Steiner M, Streiner DL, Steinberg S, et al. The measurement of premenstrual mood symptoms. J Affect Disord. 1999;53:269–73.PubMedCrossRefGoogle Scholar
  19. 19.
    Pearlstein TB, Frank E, Rivera-Tovar A, Thoft JS, Jacobs E, Mieczkowski TA. Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder. J Affect Disord. 1990;20:129–34.PubMedCrossRefGoogle Scholar
  20. 20.
    Paykel ES, Hollyman JA, Freeling P, Sedgwick P. Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial. J Affect Disord. 1988;14:83–95.PubMedCrossRefGoogle Scholar
  21. 21.
    Parnetti L, Sommacal S, Morselli Labate AM, Senin U. Multicentre controlled randomised double-blind pracebo study of minaprine in elderly patients suffering from prolonged depressive reaction. Drug Invest. 1993;6:181–8.Google Scholar
  22. 22.
    Williams JW Jr., Barrett J, Oxman T, et al. Treatment of dysthymia and minor depression in primary care: a randomized controlled trial in older adults. JAMA. 2000;284:1519–26.PubMedCrossRefGoogle Scholar
  23. 23.
    Miranda J, Munoz R. Intervention for minor depression in primary care patients. Psychosom Med. 1994;56:136–41.PubMedGoogle Scholar
  24. 24.
    Lynch DJ, Tamburrino MB, Nagel R. Telephone counseling for patients with minor depression: preliminary findings in a family practice setting. J Fam Pract. 1997;44:293–8.PubMedGoogle Scholar
  25. 25.
    Katon W, Von Korff M, Lin E, et al. Collaborative management to achieve treatment guidelines. Impact on depression in primary care. JAMA. 1995;273:1026–31.PubMedCrossRefGoogle Scholar
  26. 26.
    Katon W, Robinson P, Von Korff M, et al. A multifaceted intervention to improve treatment of depression in primary care. Arch Gen Psychiatry. 1996;53:924–32.PubMedGoogle Scholar
  27. 27.
    Halbreich U, Bergeron R. Intermittent (luteal phase) dosing of sertraline effective in PMDD [abstract]. Int J Neuropsychopharmacol. 2000;3:241S-248S.Google Scholar
  28. 28.
    Freeman EW, Rickels K, Sondheimer SJ, Polansky M. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA. 1995;274:51–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Lam RW, Carter D, Misri S, Kuan AJ, Yatham LN, Zis AP. A controlled study of light therapy in women with late luteal phase dysphoric disorder. Psychiatry Res. 1999;86:185–92.PubMedCrossRefGoogle Scholar
  30. 30.
    Rausch JL, Janowsky DS, Golshan S, Kuhn K, Risch SC. Atenolol treatment of late luteal phase dysphoric disorder. J Affect Disord. 1988;15:141–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Sundblad C, Modigh K, Andersch B, Eriksson E. Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr Scand. 1992;85:39–47.PubMedGoogle Scholar
  32. 32.
    Sundblad C, Hedberg MA, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology. 1993;9:133–45.PubMedGoogle Scholar
  33. 33.
    Harrison WM, Endicott J, Nee J. Treatment of premenstrual dysphoria with alprazolam. A controlled study. Arch Gen Psychiatry. 1990;47:270–5.PubMedGoogle Scholar
  34. 34.
    Berger CP, Presser B. Alprazolam in the treatment of two subsamples of patients with late luteal phase dysphoric disorder: a double-blind, placebo-controlled crossover study. Obstet Gynecol. 1994;84:379–85.PubMedGoogle Scholar
  35. 35.
    Rickels K, Freeman EW. Prior benzodiazepine exposure and benzodiazepine treatment outcome. J Clin Psychiatry. 2000;61:409–13.PubMedCrossRefGoogle Scholar
  36. 36.
    Morse CA, Dennerstein L, Farrell E, Varnavides K. A comparison of hormone therapy, coping skills training, and relaxation for the relief of premenstrual syndrome. J Behav Med. 1991;14:469–89.PubMedCrossRefGoogle Scholar
  37. 37.
    Kirkby RJ. Changes in premenstrual symptoms and irrational thinking following cognitive-behavioral coping skills training. J Consult Clin Psychol. 1994;62:1026–32.PubMedCrossRefGoogle Scholar
  38. 38.
    Blake F, Salkovskis P, Gath D, Day A, Garrod A. Cognitive therapy for premenstrual syndrome: a controlled trial. J Psychosom Res. 1998;45:307–18.PubMedCrossRefGoogle Scholar
  39. 39.
    Christensen AP, Oei TP. The efficacy of cognitive behaviour therapy in treating premenstrual dysphoric changes. J Affect Disord. 1995;33:57–63.PubMedCrossRefGoogle Scholar
  40. 40.
    Corney RH, Stanton R, Newell R. Comparison of progesterone, placebo and behavioural psychotherapy in the treatment of premenstrual syndrome. J Psychosom Obstet Gynaecol. 1990;11:211–20.Google Scholar
  41. 41.
    Freeman EW, Rickels K, Sondheimer SJ, Polansky M. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch Gen Psychiatry. 1999;56:932–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Eriksson E, Hedberg MA, Andersch B, Sundblad C. The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology. 1995;12:167–76.PubMedCrossRefGoogle Scholar
  43. 43.
    Linde K, Mulrow CD. St. John’s wort for depression [Cochrane Review]. In: The Cochrane Library. Issue 3,. Oxford: Update Software; 1999.Google Scholar
  44. 44.
    Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St John’s wort in major depression: a randomized controlled trial. JAMA. 2001;285:1978–86.PubMedCrossRefGoogle Scholar
  45. 45.
    North TC, McCullagh P, Tran ZV. Effect of exercise on depression. Exerc Sport Sci Rev. 1990;18:379–415.PubMedCrossRefGoogle Scholar
  46. 46.
    McNeil JK, LeBlanc EM, Joyner M. The effect of exercise on depressive symptoms in the moderately depressed elderly. Psychol Aging. 1991;6:487–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Veale D, Le Fevre K, Pantelis C, de Souza V, Mann A, Sargeant A. Aerobic exercise in the adjunctive treatment of depression: a randomized controlled trial. J R Soc Med. 1992;85:541–4.PubMedGoogle Scholar
  48. 48.
    Blumenthal JA, Babyak MA, Moore KA, et al. Effects of exercise training on older patients with major depression. Arch Intern Med. 1999;159:2349–56.PubMedCrossRefGoogle Scholar
  49. 49.
    Wyatt KM, Dimmock PW, Jones PW, Shaughn O’Brien PM. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ. 1999;318:1375–81.PubMedGoogle Scholar
  50. 50.
    Lemos D. The effects of aerobic training on women who suffer from premenstrual syndrome. Dissert Abstracts Int. 1991;52:563.Google Scholar
  51. 51.
    Bibi KW. The effects of aerobic training on women who suffer from premenstrual syndrome. Dissert Abstracts Int. 1995;56:6678.Google Scholar
  52. 52.
    Budeiri D, Li Wan Po A, Dornan JC. Is evening primrose oil of value in the treatment of premenstrual syndrome? Control Clin Trials. 1996;17:60–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Simon GE, Von Korff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA. 1996;275:1897–902.PubMedCrossRefGoogle Scholar
  54. 54.
    Parry GJ. Sensory neuropathy with low dose pyridoxine. Neurology. 1985;35:1466–8.PubMedGoogle Scholar
  55. 55.
    Drug interactions with St. John’s wort. Med Lett Drugs Ther. 2000;42:56.Google Scholar
  56. 56.
    Wolfe RM. Antidepressant withdrawal reactions. Am Fam Physician. 1997;56:455–62.PubMedGoogle Scholar
  57. 57.
    American Psychiatric Association Practice Guidelines. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry. 2000;157(Suppl 4):1S-45S.Google Scholar
  58. 58.
    Snow V, Lascher S, Mottur-Pilson C. Pharmacologic treatment of acute major depression and dysthymia. American College of Physicians-American Society of Internal Medicine. Ann Intern Med. 2000;132:738–42.PubMedGoogle Scholar

Copyright information

© Society of General Internal Medicine 2002

Authors and Affiliations

  1. 1.the Robert Wood Johnson Clinical Scholars ProgramUniversity of Washington, and Veterans Affairs Puget Sound Health Care SystemSeattle
  2. 2.the Center for Health Services Research in Primary Care, HSR&D, Department of Veterans Affairs Medical CenterDuke University Medical CenterDurham

Personalised recommendations